{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:25:02Z","timestamp":1768879502801,"version":"3.49.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2012,9,12]],"date-time":"2012-09-12T00:00:00Z","timestamp":1347408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose.<\/jats:title>\n                  <jats:p>Although the impact of imatinib in improving survival outcomes in chronic myelogenous leukemia (CML) patients has been widely reported, its impact on mortality from CML has not been evaluated. A survival benefit demonstrated in clinical trials does not simply translate to a decrease in mortality. To evaluate the impact of imatinib on the public health, we estimated the age-standardized mortality rate of CML patients in Japan and the U.S. using vital statistics data for Japan and data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute for the U.S.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods.<\/jats:title>\n                  <jats:p>The period covered in this analysis is 1993\u20132008, during which 64,203 patients in Japan and 26,888 patients in nine registries in the U.S. died as a result of CML. We used joinpoint regression analysis to evaluate the significance of trends in mortality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>Estimated age-standardized mortality rates decreased significantly in both countries after the availability of imatinib. The annual percent changes (95% confidence interval) in the U.S. were \u221212.3% (\u221214.8% to \u22129.7%) for men and \u221211.6% (\u221213.1% to \u221210.1%) for women. In Japan, these were \u221220.8% (\u221236.2% to \u22121.6%) for men and \u221215.6% (\u221218.8% to \u221212.2%) for women. The period of change in the mortality trend seems to correlate with the period in which imatinib appeared in the two countries. The CML mortality rate in 2008 was nearly 30% that of the 1993 level.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>This is one example of the advent of a single new drug changing the picture of a single disease, CML. These results may encourage further development of drugs based on the concept of molecular targeting.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2012-0197","type":"journal-article","created":{"date-parts":[[2012,9,13]],"date-time":"2012-09-13T00:26:48Z","timestamp":1347496008000},"page":"1547-1550","source":"Crossref","is-referenced-by-count":20,"title":["Decreasing Trend in Mortality of Chronic Myelogenous Leukemia Patients After Introduction of Imatinib in Japan and the U.S."],"prefix":"10.1093","volume":"17","author":[{"given":"Dai","family":"Chihara","sequence":"first","affiliation":[{"name":"a Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan;"},{"name":"b Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidemi","family":"Ito","sequence":"additional","affiliation":[{"name":"a Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Matsuda","sequence":"additional","affiliation":[{"name":"c Surveillance Division, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Katanoda","sequence":"additional","affiliation":[{"name":"c Surveillance Division, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Shibata","sequence":"additional","affiliation":[{"name":"c Surveillance Division, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumiko","family":"Saika","sequence":"additional","affiliation":[{"name":"c Surveillance Division, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomotaka","family":"Sobue","sequence":"additional","affiliation":[{"name":"d Department of Environmental Medicine and Population Science, Osaka University Graduate School of Medicine, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keitaro","family":"Matsuo","sequence":"additional","affiliation":[{"name":"a Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan;"},{"name":"b Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2012,9,12]]},"reference":[{"key":"2021122308234036500_B1","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa020798","article-title":"Aspirin and mortality from coronary bypass surgery","volume":"347","author":"Mangano","year":"2002","journal-title":"N Engl J Med"},{"key":"2021122308234036500_B2","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.2105\/AJPH.66.12.1180","article-title":"The effect of antibiotics on mortality from infectious diseases in Sweden and Finland","volume":"66","author":"Hemminki","year":"1976","journal-title":"Am J Public Health"},{"key":"2021122308234036500_B3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/bmj.2.2166.27","article-title":"A century of vaccination: Small-pox epidemics and small-pox mortality before and since vaccination came into use","volume":"2","author":"Edwardes","year":"1902","journal-title":"Br Med J"},{"key":"2021122308234036500_B4","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/306277a0","article-title":"Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia","volume":"306","author":"Bartram","year":"1983","journal-title":"Nature"},{"key":"2021122308234036500_B5","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"2021122308234036500_B6","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"2021122308234036500_B7","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","article-title":"Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: A single-institution historical experience","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"2021122308234036500_B8","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3324\/haematol.13045","article-title":"Recent trends in long-term survival of patients with chronic myelocytic leukemia: Disclosing the impact of advances in therapy on the population level","volume":"93","author":"Brenner","year":"2008","journal-title":"Haematologica"},{"key":"2021122308234036500_B9","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122308234036500_B10","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122308234036500_B11","volume-title":"Surveillance, Epidemiology, and End Results. US Population Data - 1969\u20132009","author":"National Cancer Institute"},{"key":"2021122308234036500_B12","volume-title":"Surveillance, Epidemiology, and End Results","author":"National Cancer Institute"},{"key":"2021122308234036500_B13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1023\/A:1014344519276","article-title":"Practical implications of imposing a new world standard population","volume":"13","author":"Bray","year":"2002","journal-title":"Cancer Causes Control"},{"key":"2021122308234036500_B14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z","article-title":"Permutation tests for joinpoint regression with applications to cancer rates","volume":"19","author":"Kim","year":"2000","journal-title":"Stat Med"},{"key":"2021122308234036500_B15","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0140-6736(02)08020-0","article-title":"Long-term effects of mammography screening: Updated overview of the Swedish randomised trials","volume":"359","author":"Nystr\u00f6m","year":"2002","journal-title":"Lancet"},{"key":"2021122308234036500_B16","first-page":"2157","article-title":"Effect of organized screening on incidence and mortality of cervical cancer in Denmark","volume":"49","author":"Lynge","year":"1989","journal-title":"Cancer Res"},{"key":"2021122308234036500_B17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/jjco\/hyr184","article-title":"Cancer incidence and incidence rates in Japan in 2006: Based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project","volume":"42","author":"Matsuda","year":"2012","journal-title":"Jpn J Clin Oncol"},{"key":"2021122308234036500_B18","volume-title":"WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues","author":"Jaffe","year":"2001"},{"key":"2021122308234036500_B19","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1158\/1055-9965.EPI-09-0028","article-title":"Obesity, weight gain, and risk of chronic myeloid leukemia","volume":"18","author":"Strom","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2021122308234036500_B20","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/oem.58.11.722","article-title":"Are occupational, hobby, or lifestyle exposures associated with Philadelphia chromosome positive chronic myeloid leukaemia?","volume":"58","author":"Bj\u00f6rk","year":"2001","journal-title":"Occup Environ Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2012-0197","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2012-0197","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/12\/1547\/41860031\/oncolo_17_12_1547.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/12\/1547\/41860031\/oncolo_17_12_1547.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T22:00:55Z","timestamp":1640296855000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/17\/12\/1547\/6403271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,12]]},"references-count":20,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2012,9,12]]},"published-print":{"date-parts":[[2012,12,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2012-0197","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,12,1]]},"published":{"date-parts":[[2012,9,12]]}}}